Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$2.26 -0.9%	$3.30	$2.09 ▼ $5.64	$150.36M	1.54	1.43 million shs	472,242 shs
DERM Journey Medical	$7.08 +0.1%	$7.14	$3.54 ▼ $8.90	$164.96M	0.8	109,728 shs	101,722 shs
EQ Equillium	$1.56 +36.8%	$0.50	$0.27 ▼ $1.57	$55.72M	1.15	3.44 million shs	4.85 million shs
GLSI Greenwich LifeSciences	$11.85 -0.8%	$10.69	$8.06 ▼ $16.50	$161.52M	1.65	58,243 shs	38,986 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-0.87%	-6.94%	-41.69%	-20.83%	-0.87%
DERM Journey Medical	0.00%	-2.48%	-1.67%	+3.67%	+58.88%
EQ Equillium	-5.00%	+22.58%	+175.30%	+187.88%	+37.95%
GLSI Greenwich LifeSciences	+4.10%	+1.36%	+1.53%	+21.84%	-13.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.6216 of 5 stars	3.4	1.0	0.6	1.7	0.6
DERM Journey Medical	1.7193 of 5 stars	3.3	1.0	2.3	0.8	0.6
EQ Equillium	0.9042 of 5 stars	1.0	5.0	1.9	1.7	0.0
GLSI Greenwich LifeSciences	1.428 of 5 stars	3.5	0.0	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	346.90% Upside
DERM Journey Medical	2.50	Moderate Buy	$10.83	53.01% Upside
EQ Equillium	2.00	Hold	$1.00	-35.90% Downside
GLSI Greenwich LifeSciences	3.00	Buy	$42.00	254.43% Upside

Current Analyst Ratings Breakdown

Latest EQ, GLSI, CRDF, and DERM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	GLSI Greenwich LifeSciences	Noble Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/15/2025	DERM Journey Medical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/13/2025	DERM Journey Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $13.00
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	221.11	N/A	N/A	$0.88 per share	2.57
DERM Journey Medical	$56.13M	2.94	N/A	N/A	$0.83 per share	8.53
EQ Equillium	$41.10M	1.36	N/A	N/A	$0.14 per share	11.14
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.11 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	11/6/2025 (Estimated)
DERM Journey Medical	-$14.67M	-$0.38	N/A	N/A	N/A	-15.49%	-48.69%	-11.26%	N/A
EQ Equillium	-$8.07M	-$0.56	N/A	N/A	N/A	-19.62%	-139.56%	-90.56%	N/A
GLSI Greenwich LifeSciences	-$15.79M	-$1.36	N/A	N/A	N/A	N/A	-700.90%	-455.64%	N/A

Latest EQ, GLSI, CRDF, and DERM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/14/2025	Q2 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.30	-$0.06	-$0.30	N/A	N/A
8/12/2025	Q2 2025	DERM Journey Medical	-$0.07	-$0.16	-$0.09	-$0.16	$14.93 million	$15.01 million
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	4.42	4.42
DERM Journey Medical	1.11	1.27	0.95
EQ Equillium	N/A	1.65	2.70
GLSI Greenwich LifeSciences	N/A	1.85	1.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
DERM Journey Medical	7.25%
EQ Equillium	27.05%
GLSI Greenwich LifeSciences	4.16%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
DERM Journey Medical	15.03%
EQ Equillium	31.60%
GLSI Greenwich LifeSciences	51.67%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
EQ Equillium	40	35.72 million	24.43 million	Not Optionable
GLSI Greenwich LifeSciences	3	13.63 million	6.46 million	Not Optionable

EQ, GLSI, CRDF, and DERM Headlines

Recent News About These Companies

Greenwich LifeSciences initiated with an Outperform at Noble Capital

August 20 at 4:38 PM | msn.com

Greenwich LifeSciences, Inc. Gains Coverage from Noble Capital Markets Amid Phase III Trial of GLSI-100 for Breast Cancer

August 20 at 9:31 AM | quiverquant.comQ

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

August 20 at 9:25 AM | globenewswire.com

Greenwich LifeSciences to build out internal clinical trial operations team

August 20 at 2:25 AM | msn.com

Greenwich LifeSciences, Inc. Expands Internal Clinical Trial Management Team for FLAMINGO-01 Phase III Study

August 19 at 6:51 AM | quiverquant.comQ

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

August 19 at 6:00 AM | globenewswire.com

Greenwich LifeSciences (NASDAQ:GLSI) Announces Quarterly Earnings Results

August 18 at 1:52 PM | marketbeat.com

Owning 53% in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) means that insiders are heavily invested in the company's future

August 16, 2025 | finance.yahoo.com

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

August 13, 2025 | globenewswire.com

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 2.5% - Still a Buy?

August 12, 2025 | marketbeat.com

Greenwich LifeSciences, Inc. Provides Update on CEO Interviews and Corporate Events Related to GLSI-100 Development

August 11, 2025 | quiverquant.comQ

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

August 11, 2025 | globenewswire.com

Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 27, 2025 | azcentral.comA

Greenwich LifeSciences: What The Recent Data Do For The Investment Thesis

May 9, 2025 | seekingalpha.com

Snehal Patel Buys 3,600 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

April 30, 2025 | insidertrades.com

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 5,400 Shares

April 23, 2025 | insidertrades.com

Greenwich LifeSciences price target raised to $39 from $38 at H.C. Wainwright

April 22, 2025 | markets.businessinsider.com

Why Greenwich LifeSciences, Inc.’s (GLSI) Stock Is Down 5.88%

April 15, 2025 | aaii.comA

Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 3,600 Shares of Stock

April 9, 2025 | insidertrades.com

Snehal Patel Acquires 5,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

April 8, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EQ, GLSI, CRDF, and DERM Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$2.26 -0.02 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$2.28 +0.03 (+1.11%)

As of 05:56 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Journey Medical NASDAQ:DERM

$7.08 +0.01 (+0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$7.08 0.00 (-0.07%)

As of 04:20 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Equillium NASDAQ:EQ

$1.56 +0.42 (+36.84%)

Closing price 04:00 PM Eastern

Extended Trading

$1.52 -0.04 (-2.24%)

As of 06:45 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Greenwich LifeSciences NASDAQ:GLSI

$11.85 -0.09 (-0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$12.02 +0.17 (+1.39%)

As of 05:00 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time